LONDON and BUDAPEST, Hungary, October 16, 2017 /PRNewswire/ --
ChemPass, an artificial intelligence technology company and LifeArc, a medical research charity, announced today that they have successfully completed the first phase of their evaluation of ChemPass' technology for its ability to support LifeArc's medicinal chemistry programs.
The results indicate that the ChemPass technology can effectively support medicinal chemistry programs and widen the chemical space for lead optimisation.
The application of the ChemPass technology for lead generation and lead optimisation resulted in the expansion of the accessible chemical space, and created novel analogs and scaffold suggestions that would have likely been missed without this technology. The results show that the ChemPass technology could add value to medicinal chemistry programs.
Dr Andy Merritt, Head of Chemistry and Associate Director at LifeArc said: "We assessed the technology in real life programs and were encouraged by both the novelty and quality of the ideas it generated. We look forward to applying it to more programs in future."
Dr Gergely Makara, CEO of ChemPass added: "We are proud that our technology widened the chemical space for the research programs and provided valuable ideas for LifeArc's medicinal chemistry programs. We look forward to continuing our collaboration and adding value to additional lead optimisation projects in the LifeArc R&D pipeline."
ChemPass is an artificial intelligence design technology company focusing on the development of software solutions that help chemists and medicinal chemists design novel scaffolds and lead analogs to be able to reach a significantly expanded chemical space.
About Life Arc
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.
The new name reflects the charity's purpose: to be the arc or bridge between research and improving patients' lives.
LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.
The charity has dedicated laboratories in Stevenage where around 80 scientists work on antibody and small molecule projects, while the Edinburgh lab progresses diagnostics development.
So far, LifeArc's work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antibiotic resistance.
http://www.lifearc.org , Twitter: @lifearc1